42
Participants
Start Date
April 12, 2018
Primary Completion Date
June 1, 2020
Study Completion Date
June 1, 2020
3 mg/kg Q3W MSB2311 Injection
An intravenous infusion with concentration from 3 mg/kg (Q3W)
10 mg/kg Q3W MSB2311 Injection
An intravenous infusion with concentration from 10 mg/kg (Q3W)
20 mg/kg Q3W MSB2311 Injection
An intravenous infusion with concentration from 20 mg/kg (Q3W)
10 mg/kg Q2W MSB2311 Injection
An intravenous infusion with concentration from 10 mg/kg (Q2W)
South Texas Accelerated Research Therapeutics, San Antonio
Suzhou Transcenta Therapeutics Co., Ltd.
INDUSTRY